SFGV

The Week

Medtronic rose 1.04% on the week to close at $102.86, lagging the S&P 500 by roughly 1.47 percentage points after the index gained 2.51%. The stock moved in two directions: it touched a high of $103.69 on Monday, then pulled back to $100.80 on Tuesday and $100.92 on Thursday, before regaining ground on Friday (13 November) to end at $102.86. Weekly amplitude was 3.57%. Average daily volume of 5.31m shares ran about 44% below the 60-day median, reflecting a quiet tape.

Key Events

The week’s news flow centred on surgical robotics, renal denervation data and valuation talk. On Monday (9 November), Cornerstone Robotics hosted its inaugural Surgical Futures Forum in Hong Kong to discuss robotics and accessible surgical care; the same day the company received around $700m in strategic investment, drawing attention to the surgical robotics space. On Tuesday (10 November), coverage examined how positive renal denervation data may affect Medtronic’s share price, and on Wednesday (11 November) the stock underperformed its peers. A report on Thursday (12 November) suggested the shares may be near fair value after a 54% run. There were no material company filings during the week.

Analyst Ratings

Medtronic is covered by 30 analysts as of this week: 17 rate it buy, 2 over, 11 hold, with no under or sell ratings. The consensus recommendation is buy, with a consensus target price of $105, about 2.08% above the latest close of $102.86. Target prices range from $85 to $121, a wide spread that points to divergence across the Street. In the medical devices industry, Medtronic ranks 4th among 142 names in analyst coverage.

The Week Ahead

A heavy macro calendar is due next week. The New York Fed manufacturing index lands on Monday (16 November), followed on Tuesday (17 November) by import prices, retail sales, industrial production and the NAHB housing market index. These releases may shift expectations around medical device demand. Medtronic reports fiscal Q2 2027 results before the open on 24 November; estimates call for EPS of $1.0195 and revenue of $9.479bn, implying roughly 7% year-on-year revenue growth. Further readings on renal denervation data and the surgical robotics theme are also worth watching.

In Short

Medtronic closed slightly higher in a low-volume week and underperformed the broader market. The Street leans constructive, with 19 of 30 analysts assigning buy or over ratings and a consensus target slightly above spot, but the $36 spread between high and low targets points to real disagreement. Valuation sits at roughly 24x earnings and 2.51x book, a moderate-to-elevated zone. The next catalyst arrives with the 24 November earnings report, which will test the growth expectations attached to renal denervation and other new pipelines, alongside the macro data flow.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.